Sold as Menadione. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Menadione (sold as Menadione), with 0 new uses approved and 0 published complete response letters.
| An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 SubstratesUlcerative Colitis, Crohn's Disease · Sanofi | Phase 1 | Not yet recruiting | Nov 6, 2026 |
| Danang Cerebral Venous Thrombosis RegistryCerebral Venous Sinus Thrombosis, Stroke · Da Nang Hospital | — | Recruiting | Oct 22, 2026 |
| Anticoagulant Cessation After Antiphospholipid Autoantibodies Loss in Thrombotic Antiphospholipid SyndromeAntiphospholipid Syndrome, Thrombotic Antiphospholipid Syndrome · Assistance Publique - Hôpitaux de Paris | Phase 3 | Not yet recruiting | Oct 15, 2026 |
| Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic HyperlipidemiaLipid Metabolism Disorders · National Heart, Lung, and Blood Institute (NHLBI) | Not applicable | Not yet recruiting | Jul 21, 2026 |
| An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative ColitisActive Ulcerative Colitis · Hoffmann-La Roche | Phase 1 | Recruiting | Jun 24, 2026 |
| Optimizing Anticoagulation in Pregnancies With Mechanical Heart ValvesPregnancy, Prosthetic Heart Valve · Mount Sinai Hospital, Canada | Not applicable | Recruiting | Jun 22, 2026 |
| STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD PumpLVAD (Left Ventricular Assist Device) Thrombosis, LVAD · China National Center for Cardiovascular Diseases | Phase 4 | Not yet recruiting | Jun 12, 2026 |
| Antithrombotic Treatment Strategies in Cervical Artery DissectionCervical Artery Dissection · University Department of Geriatric Medicine FELIX PLATTER | Not applicable | Not yet recruiting | Jun 10, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Lilly